Phase 1 study of combinatorial sorafenib, <scp>G‐CSF</scp>, and plerixafor treatment in relapsed/refractory, <scp>FLT3‐ITD</scp>‐mutated acute myelogenous leukemia patients
Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Naval Daver(The University of Texas MD Anderson Cancer Center), Zhihong Zeng(The University of Texas MD Anderson Cancer Center), Mary Ann Kelly(The University of Texas MD Anderson Cancer Center), Hsiang‐Chun Chen(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Teresa McQueen(Leukemia Research Foundation), Ru‐Yiu Wang(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center)
Cited by 38
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k